Revolutionizing Sickle Cell Disease Treatment: Unveiling CRISPR and Lentiviral Therapies—Navigating Complexities in Access, Equity, and Global Health Dynamics.
Advancing Sickle Cell Disease Treatment: Addressing Access Challenges In this editorial, we discuss the recent approval by the U.S. Food and Drug Administration (FDA) of two new treatments, Casgevy and Lyfgenia, for sickle cell disease (SCD) in patients aged 12 and older. These treatments are signif...
| Publicado en: | Plasmatology Vol. 18; pp. 1 - 3 |
|---|---|
| Autor principal: | |
| Formato: | letter Journal Article |
| Publicado: |
Sage Publications Inc.
5/20/2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=177377185&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 177377185 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 26348535 MXRV jtl: Plasmatology issn: 26348535 maglogo: Y pubinfo: dt: 5/20/2024 vid: 18 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 177377185 177377185 177377185 10.1177/26348535241254682 177377185 ppf: 1 ppct: 2 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Revolutionizing Sickle Cell Disease Treatment: Unveiling CRISPR and Lentiviral Therapies—Navigating Complexities in Access, Equity, and Global Health Dynamics. aug: au: Ashinze, Patrick affil: Faculty of Clinical Sciences, College of Health Sciences, 361345 University of Ilorin, Ilorin, Nigeria sug: subj: Clustered Regularly Interspaced Short Palindromic Repeats Anemia, Sickle Cell Therapy World Health Gene Therapy United States Food and Drug Administration Gene Editing Drug Approval Hematologic Diseases Individualized Medicine Health Services Accessibility Quality of Life ab: Advancing Sickle Cell Disease Treatment: Addressing Access Challenges In this editorial, we discuss the recent approval by the U.S. Food and Drug Administration (FDA) of two new treatments, Casgevy and Lyfgenia, for sickle cell disease (SCD) in patients aged 12 and older. These treatments are significant because Casgevy is the first FDA-approved therapy to use a new genome editing technology. This approval represents a big step forward in gene therapy and in the treatment of sickle cell disease which is clinically characterised by the complications of an unresponsive hemoglobin. However, while celebrating this achievement, we need to think about how to make sure everyone who needs these treatments can get them, especially in Africa where SCD affects many people. It's not just about making the treatments, but also about making sure they reach the people who need them the most. This means we need to work on things like logistics (how to get the treatments to the right places) and political will (making sure governments support getting these treatments to everyone who needs them). In the end, it's not enough to have these new treatments available - we need to make sure they actually help the people who need them most, wherever they are in the world. pubtype: Academic Journal doctype: letter Journal Article ougenre: Unknown language: English refInfo: holdings: @attributes: islocal: N |
|---|